📊 MRKR Key Takeaways
Is Marker Therapeutics, Inc. (MRKR) a Good Investment?
Marker Therapeutics faces severe fundamental deterioration with revenue collapsing 46.2% YoY to only $751.7K, operating losses of $4.1M, and persistent negative returns on equity and assets. While a strong cash position ($14.9M) and zero debt provide near-term runway of ~10 years at current burn rates, the absence of visible growth catalysts, declining revenue, and unsustainable operating losses indicate a failed or severely distressed business model requiring restructuring.
Fundamentals show a small, shrinking revenue base with deeply negative margins and sustained operating losses. While liquidity is strong with substantial cash and no debt, the cash burn suggests a limited runway and potential need for external financing. Without clear, durable revenue traction, risk dominates near-term fundamentals.
Why Buy Marker Therapeutics, Inc. Stock? MRKR Key Strengths
- Exceptional cash reserves of $14.9M relative to total liabilities of $3.6M providing substantial operational runway
- Zero long-term debt and excellent liquidity ratios (4.79x current ratio) minimizing financial distress risk in near term
- Improving EPS trajectory year-over-year (+33.6%) despite ongoing losses suggesting cost control efforts
- Strong liquidity and cash position (8.39x current ratio, $16.07M cash)
- No debt and low liabilities, reducing financial risk
- Improved EPS YoY and stabilized net loss indicate some operating discipline
MRKR Stock Risks: Marker Therapeutics, Inc. Investment Risks
- Severe revenue contraction of 46.2% YoY with minimal revenue base of $751.7K indicating failed product commercialization or market rejection
- Operating losses of $4.1M on near-zero revenue demonstrate fundamentally non-viable business economics with -541.8% operating margin
- Negative ROE (-23.0%) and ROA (-18.2%) indicate systematic shareholder value destruction with no path to profitability evident
- Continuous operating cash burn of $1.4M annually suggests unsustainable cash consumption despite minimal operational activity
- Absence of disclosed clinical pipeline progress, product approvals, or strategic partnerships indicating stalled development
- Cash runway risk and potential dilution given ~$12M annual burn vs. $16M cash
- Revenue decline (-46% YoY) undermines path to scale
- Persistently negative margins and ROE/ROA indicate ongoing value erosion
Key Metrics to Watch
- Revenue trend stabilization - critical to identify whether decline continues or reverses with new product launches
- Operating cash flow dynamics - monthly burn rate and cash runway exhaustion timeline
- Pipeline advancement disclosures - FDA approvals, clinical trial progress, or licensing deals indicating future revenue potential
- Operating cash flow (burn rate)
- Cash & equivalents and months of runway
Marker Therapeutics, Inc. (MRKR) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.79x current ratio provides a solid financial cushion.
MRKR Profit Margin, ROE & Profitability Analysis
MRKR vs Healthcare Sector: How Marker Therapeutics, Inc. Compares
How Marker Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Marker Therapeutics, Inc. Stock Overvalued? MRKR Valuation Analysis 2026
Based on fundamental analysis, Marker Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Marker Therapeutics, Inc. Balance Sheet: MRKR Debt, Cash & Liquidity
MRKR Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Marker Therapeutics, Inc.'s revenue has grown significantly by 431% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.19 indicates the company is currently unprofitable.
MRKR Revenue Growth, EPS Growth & YoY Performance
MRKR Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $349.1K | -$3.2M | $-0.16 |
| Q3 2025 | $1.2M | -$2.0M | $-0.12 |
| Q2 2025 | $861.2K | -$2.2M | $-0.25 |
| Q1 2025 | $349.1K | -$2.4M | $-0.27 |
| Q3 2024 | $257.6K | -$2.3M | $-0.26 |
| Q2 2024 | $762.7K | -$2.2M | $-0.25 |
| Q1 2024 | $1.2M | -$2.4M | $-0.27 |
| Q3 2023 | $257.6K | -$3.0M | $-0.34 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Marker Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
MRKR SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Marker Therapeutics, Inc. (CIK: 0001094038)
📋 Recent SEC Filings
❓ Frequently Asked Questions about MRKR
What is the AI rating for MRKR?
Marker Therapeutics, Inc. (MRKR) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (SELL) with 72% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are MRKR's key strengths?
Claude: Exceptional cash reserves of $14.9M relative to total liabilities of $3.6M providing substantial operational runway. Zero long-term debt and excellent liquidity ratios (4.79x current ratio) minimizing financial distress risk in near term. ChatGPT: Strong liquidity and cash position (8.39x current ratio, $16.07M cash). No debt and low liabilities, reducing financial risk.
What are the risks of investing in MRKR?
Claude: Severe revenue contraction of 46.2% YoY with minimal revenue base of $751.7K indicating failed product commercialization or market rejection. Operating losses of $4.1M on near-zero revenue demonstrate fundamentally non-viable business economics with -541.8% operating margin. ChatGPT: Cash runway risk and potential dilution given ~$12M annual burn vs. $16M cash. Revenue decline (-46% YoY) undermines path to scale.
What is MRKR's revenue and growth?
Marker Therapeutics, Inc. reported revenue of $751.7K.
Does MRKR pay dividends?
Marker Therapeutics, Inc. does not currently pay dividends.
Where can I find MRKR SEC filings?
Official SEC filings for Marker Therapeutics, Inc. (CIK: 0001094038) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MRKR's EPS?
Marker Therapeutics, Inc. has a diluted EPS of $-0.16.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is MRKR a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Marker Therapeutics, Inc. has a SELL rating with 72% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is MRKR stock overvalued or undervalued?
Valuation metrics for MRKR: ROE of -23.0% (sector avg: 15%), net margin of -423.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy MRKR stock in 2026?
Our dual AI analysis gives Marker Therapeutics, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is MRKR's free cash flow?
Marker Therapeutics, Inc.'s operating cash flow is $-1.4M, with capital expenditures of $99.8K. FCF margin is -200.1%.
How does MRKR compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -423.0% (avg: 12%), ROE -23.0% (avg: 15%), current ratio 4.79 (avg: 2).